|
|
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.
Number of employees : 17 100 people.
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | Discovery and Safety Assessment | 1,317 | 58.1% | 1,619 | 61.8% | +22.94% | | Research Models & Services | 519.68 | 22.9% | 537.09 | 20.5% | +3.35% | | Manufacturing Support | 429.56 | 19% | 465.14 | 17.7% | +8.28% |
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | United States | 1,268 | 55.9% | 1,471 | 56.1% | +16.05% | | Europe | 643.96 | 28.4% | 726.42 | 27.7% | +12.81% | | Canada | 206.38 | 9.1% | 271.99 | 10.4% | +31.79% | | Asia Pacific | 142.50 | 6.3% | 146.22 | 5.6% | +2.61% | | Other | 5.64 | 0.2% | 5.50 | 0.2% | -2.46% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
49,888,626 |
49,009,415 |
98.2% |
146,000 |
0.3% |
98.2% |
|
|
|
| Name | Equities | % | | Capital Research & Management Co. (World Investors) | 5,555,000 |
11.2% | | The Vanguard Group, Inc. | 4,839,699 |
9.73% | | Capital Research & Management Co. | 4,355,000 |
8.76% | | JANA Partners LLC | 4,109,113 |
8.26% | | BAMCO, Inc. | 1,859,611 |
3.74% | | John W. Bristol & Co., Inc. (New York) | 1,824,059 |
3.67% | | Fidelity Management & Research Co. LLC | 1,768,223 |
3.55% | | Viking Global Investors LP | 1,732,229 |
3.48% | | BlackRock Fund Advisors | 1,548,015 |
3.11% | | Oppenheimer Capital | 1,408,500 |
2.83% |
|
| Company contact information |
|
Charles River Laboratories International, Inc. 251 Ballardvale Street Wilmington, MA 01887 Phone : +1.781.222.6000 Fax : +1.978.988.5665 Web : http://www.criver.com |
|
|
|
U.S. firms shield CEO pay as pandemic hits workers, investors |
Sector Biotechnology & Medical Research - NEC
Connections : Charles River Laboratories International, Inc. |
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
